Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
about
A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processingMutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infectionVirologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical PracticeAntiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Darunavir: a review of its use in the management of HIV-1 infection.HIV-associated immune complex kidney disease.GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis.Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
P2860
Q27728053-216B9CC1-462F-4C50-85BA-79CE803091C4Q34631149-E10A18E9-B1D9-4045-99C4-0A9B12170089Q35386013-2BD9D1C1-C5F3-4DCE-963D-60ACC17D8A53Q36086364-CA4A3671-A0DB-410D-BD69-9F4FEEBBD878Q36506829-07C0DBCE-77C5-4415-81AD-FE1CD502435AQ36785919-193E5938-23E1-45FA-BF4A-4F25A8A1859AQ36974067-7842BED6-B5CF-43A0-9F9E-95A9EF9C643DQ37553496-A173FD8A-DE05-4FAB-992C-F7CFB33830B4Q38111430-82336B2A-AC45-473A-9BDE-4C87E5B11BD5Q38171346-E2F1841E-8071-44B2-BD79-03DD493817E6Q38702034-30F6AD50-95D7-4831-91ED-CE459B5E6A95Q41930312-B983BB43-6ECF-4BE9-B8E8-8E9A9D56F75EQ48631709-B6759913-C372-4C09-9E10-FB3840467EBAQ53682120-1C6517D0-9687-467F-8A63-0E90002628AB
P2860
Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protease inhibitor-based antir ...... e evidence behind the options.
@en
Protease inhibitor-based antir ...... e evidence behind the options.
@nl
type
label
Protease inhibitor-based antir ...... e evidence behind the options.
@en
Protease inhibitor-based antir ...... e evidence behind the options.
@nl
prefLabel
Protease inhibitor-based antir ...... e evidence behind the options.
@en
Protease inhibitor-based antir ...... e evidence behind the options.
@nl
P356
P1476
Protease inhibitor-based antir ...... e evidence behind the options.
@en
P2093
Charles Hicks
Susanna Naggie
P304
P356
10.1093/JAC/DKQ130
P407
P577
2010-04-23T00:00:00Z